A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase II Trial of Allisartan Isoproxil in Essential Hypertensive Population at Low-Medium Risk

• Ying Li,

  Affiliation Center of Clinical Pharmacology, the Third Xiangya hospital, Central South University, Changsha, China

  ⨯
• Xiao-hui Li,

  Affiliation Department of Pharmacology, School of Pharmaceutical Sciences, Central South University, Changsha, China

  ⨯
• Zhi-jun Huang,

  Affiliation Center of Clinical Pharmacology, the Third Xiangya hospital, Central South University, Changsha, China

  ⨯
• Guo-ping Yang,

  Affiliation Center of Clinical Pharmacology, the Third Xiangya hospital, Central South University, Changsha, China

  ⨯
• Guo-gang Zhang,

  Affiliation Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha, China

  ⨯
• Shui-ping Zhao,

  Affiliation Department of Cardiology, the Second Xiangya Hospital, Central South University, Changsha, China

  ⨯
• Ying Guo,

  Affiliation Department of Cardiology, Hunan Provincial People’s Hospital, Changsha, China

  ⨯
• Shi-juan Lu,

  Affiliation Department of Cardiology, Haikou City People’s Hospital, Haikou, China

  ⨯
• Jian-lin Ma,

  Affiliation Department of Cardiology, Hainan Provincial People’s Hospital, Haikou, China

  ⨯
• Fan-bo Meng,

  Affiliation Department of Cardiology, China Japan Union Hospital of Jilin University, Changchun, China

  ⨯
• Ping Chen,

  Affiliation Department of Cardiology, Shantou Central Hospital, Shantou, China

  ⨯
• Hong Yuan

  * E-mail: yuanhongxy3@163.com

  Affiliation Center of Clinical Pharmacology, the Third Xiangya hospital, Central South University, Changsha, China

  ⨯